The Exchange has sought clarification from Onesource Specialty Pharma Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Onesource Specialty Pharma to explain why its Limited Review Report/Independent Auditor's Report for the quarter ended 31-March-2025 is not in the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The issue relates to the presentation/format of the audit report, not the financial numbers themselves. The company has not yet submitted its response, and it is awaited. Until the exchange reviews the reply, the matter remains open.
This is a routine procedural compliance query, not a financial or governance concern. Shareholders should not be alarmed, but any unusual delay in the company's response could draw additional attention from the exchange.